# A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

> **NCT02631876** · PHASE3 · COMPLETED · sponsor: **ImmunoGen, Inc.** · enrollment: 366 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Mirvetuximab soravtansine
- **DRUG:** Paclitaxel
- **DRUG:** Pegylated liposomal doxorubicin
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT02631876
- **Lead sponsor:** ImmunoGen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-02
- **Primary completion:** 2019-01
- **Final completion:** 2020-01
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2020-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02631876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02631876, "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02631876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*